semaglutide aha GLP-1 Drugs Lower Risk of Death by 44% in Obesity and Autoimmune Disease AHA 2023 | SELECT Trial:
Description
Review handling: Note refrigerated storage and cold-chain needs when applicable
Until now, leading obesity drugs in this family, including Wegovy and Mounjaro, were given by subcutaneous injection
However, PlexusDx begins all patients at medically appropriate starting levels based on medical history and safety guidelines
Its a moment that requires a shift in strategy, a transition from the initial "honeymoon phase" of the medication to a more nuanced, metabolic-focused approach
